Disclaimer. Objectives 5/30/2016

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Disclaimer. Objectives 5/30/2016"

Transcription

1 Good Clinical Practice Informed Consent Training Presented by Jacqueline Everett Clinical Trial Governance Manager, Research Integrity Disclaimer The material in this presentation has been prepared by Jacqueline Everett on behalf of The University of Sydney. This presentation provides general information about Good Clinical Practice (GCP). This information is given in summary form and does not purport to be complete. Information in this presentation, including technical clinical trial information, should not be considered as specific advice or a recommendation to researchers in relation to undertaking a clinical trial and does not take into account your particular clinical trial requirements. Before acting on any information you should consider the appropriateness of the information having regard to these matters, any relevant legislation, HREC requirements and in particular, you should seek independent accredited clinical trial training, through ARCS Australia 2 Objectives Define Good Clinical Practice (GCP) What are the PI responsibilities with GCP? What is the GCP Informed Consent process? How do you undertake informed consent in Clinical Trials? Common audit findings Tips 3 1

2 What is a Clinical Trial? Clinical Trial is a form of research designed to find out the effects of an intervention, including a treatment or diagnostic procedure. A clinical trial can involve testing a drug, a surgical procedure, other therapeutic procedures and devices, a preventive procedure, or a diagnostic device or procedure. Intervention A process or action that is the focus of a clinical study. This can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches such as surveys, education, and interviews. University of Sydney 4 What is Good Clinical Practice (GCP)? GCP is defined as a standard for the design, conduct, performance, monitoring, auditing, recording, analysis and reporting of clinical trials or studies 5 13 Principles of ICH GCP Ethics: 1. Ethical conduct of clinical trials 2. Benefits justify risks 3. Rights, safety and well being of participants prevail Protocol and science: 4. Nonclinical and clinical information supports the trial 5. Compliance with a scientifically sound, detailed protocol 6 2

3 13 Principles of ICH GCP Responsibilities: 6. HREC approval prior to initiation 7. Medical care/decisions by a qualified, licensed physician 8. Each individual is qualified (education, training, experience) to perform the tasks assigned Informed consent: 9. Freely given from every participant prior to participation 7 13 Principles of ICH GCP Data quality and integrity: All trial information is recorded, handled, and stored 10. Accurate reporting, interpretation and verification 11. Protects privacy and confidentiality of records Investigational products: 12. Conform to GMP and must be appropriately secured, stored and used per the protocol Quality control / Quality assurance 13. Systems with procedures to ensure quality of every aspect of the trial 8 Investigator (per 21 CFR (a)) who, what, why? qualified by training and experience as the appropriate expert to investigate the study in humans Responsible for the conduct of the clinical trial at the site Responsible for leading the research team 9 3

4 5/30/2016 Investigator Responsibilities Section ICH GCP Protocol adherence: No changes are allowed to the clinical trial without HREC approval expect to remove immediate hazard Properly qualified to assume responsibility for conduct of the study Personally conduct and supervise the study, including delegated responsibilities Ensure initial / continuing HREC review and approval Obtain informed consent prior to undertaking any trial related activities Report all adverse events Maintain protection of participant and data confidentiality 10 Investigator Responsibilities cont. Handle investigational products appropriately Read / Understand Investigator Brochure content, including risks and side effects Prepare and maintain adequate and accurate source information (e.g. xrays, medical records) Permit monitoring Promptly report changes in research, unanticipated risks Inform all individuals assisting with study of obligations in meeting these commitments 11 What is Informed Consent? Informed consent is an ongoing process that must occur before any clinical trialrelated procedures are conducted. The process consists of a document and a series of conversations between the clinical trial participant and the principal investigator (PI) and delegated health care professionals, as appropriate. This ongoing process of communication and mutual understanding between a participant and investigator is demonstrated by the participant s voluntary agreement to enter a clinical trial. The participant s initial and ongoing agreement is evidenced by signing of the informed consent document. The clinical trial informed consent document provides a summary of the trial, including its purpose, the treatment procedures and schedule, potential risks and benefits, and alternative treatments. It also explains the participants rights as a clinical trial participant. The informed consent process begins with the development of recruitment materials including advertisements. 12 4

5 5/30/2016 Informed Consent Guidelines Investigators must follow the International Council on Harmonisation (ICH) good clinical practice (GCP) guidelines. Section 1.28 describes the informed consent process, while the requirements and process for obtaining informed consent from a clinical trial participant are explained in section 4.8. The guiding principles of the Informed Consent process are taken from the Declaration of Helsinki, Nuremberg Code, and the Belmont Report. Nuremberg Code Voluntary consent Participant is free to stop at any time Belmont Report People are autonomous agents & should be treated with respect Informed consent must be freely and voluntarily given Those of diminished capacity require additional protection Besides following ICH GCP guidelines, investigators need to adhere to national and local regulatory requirements, sponsor requirements, and privacy and personal data security regulations applicable in the country in which the study is being conducted. 13 Informed Consent Guidelines In Australia, investigators are required to comply with the National Statement on Ethical Conduct in Human Research (2007, updated 2015). Chapter 2.2 outlines the general requirements for consent while Chapter 2.3 outlines the qualifying or waiving conditions for consent. Title 21 Code of Federal Regulations Section 50 requires the use of an HREC approved document, voluntary participation after sufficient time has lapsed for consideration, minimisation of coercion and undue influence, the information presented in an understandable manner with no exculpatory language. The FDA released a guidance document entitled Informed Consent Information Sheet in July The informed consent document must be fully approved by an Human Research Ethics Committee (HREC) prior to its use with trial participants. 14 Informed Consent ICH GCP essential elements The participant must be informed of the following: Statement that the study involves research Statement that participation is voluntary Information about purpose, duration, and procedures Number of participants involved in the study Description of risks, benefits, and alternatives Information about compensation/care for injury Statement regarding confidentiality of records Description of possible unforeseen risks Circumstances for termination without participant consent Consequences of withdrawing from the study Additional costs that may result from participation Statement that new research findings will be shared Contact information for questions/concerns 15 5

6 ls.com/investigators/informed_consent.htm 5/30/2016 Informed Consent What s Wrong? 16 Informed Consent Process Informed consent begins with the initial approach of an investigator to a potential participant (e.g., through a flyer, brochure or any advertisement regarding the clinical trial). The Principal Investigator (PI) determines if the participant has capacity to provide informed consent. The PI refers to the informed consent form when discussing the trial s risks, benefits and other aspects with the potential participant and, if required, the participant s legal representative, before any trial procedures are undertaken. A copy of the information sheet and consent form should be given to the participant for further review prior to them making a decision. The PI should give the potential participant ample time and opportunity to ask questions about the trial and discuss it with relatives and family members. If the potential participant decides to get involved in the trial, he or she provides voluntary consent by signing and dating the written informed consent document of which he or she also receives a copy. The participant has the right to withdraw consent at any time without penalty, repercussions or reason. While the PI may delegate the task of administering and obtaining informed consent to a qualified individual, he or she is ultimately responsible for ensuring the process is conducted properly. Informed consent continues until the completion of the clinical trial, or until the individual completes clinical trial participation, withdraws consent, or is withdrawn from the clinical trial. 17 Modifications to Informed Consent Informed consent documents must be revised every time new safety information becomes available or there is a change in trial procedures, participant compensation or personnel noted on the information sheet / consent form. Revisions to the informed consent document must be approved by an HREC prior to its use, and the informed consent process with the new information and documentation needs to be repeated with every clinical trial participant. The participant is then required to sign the revised consent form

7 Informed Consent Process Waiver The HREC can approve a consent procedure which does not include, or which alters, some or all of the elements of informed consent, or may waive the requirement to obtain informed consent from some or all of the research participants provided that each of the following criteria are met: The research involves no more than low risk to the participants; The waiver or alteration will not adversely affect the rights and welfare of the participants; It is impracticable to obtain consent The research could not reasonably be carried out without the waiver or alteration; and There is sufficient protection of their privacy There is an adequate plan to protect the confidentiality of data Whenever appropriate, the participants will be provided with additional pertinent information after participation. The waiver is not prohibited by State, federal, or international law. 19 Informed Consent Process Opt Out The HREC can approve opt out consent provided that each of the following criteria are met: involvement in the research carries no more than low risk to participants the public interest in the proposed activity substantially outweighs the public interest in the protection of privacy the research activity is likely to be compromised if the participation rate is not near complete, and the requirement for explicit consent would compromise the necessary level of participation reasonable attempts are made to provide all prospective participants with appropriate plain language information explaining the nature of the information to be collected, the purpose of collecting it, and the procedure to decline participation or withdraw from the research a reasonable time period is allowed between the provision of information to prospective participants and the use of their data so that an opportunity for them to decline to participate is provided before the research begins a mechanism is provided for prospective participants to obtain further information and decline to participate the data collected will be managed and maintained in accordance with relevant security standards there is a governance process in place that delineates specific responsibility for the project and for the appropriate management of the data the opt out approach is not prohibited by State, federal, or international law. 20 Informed Consent Process Considerations Careful consideration should be given to ensuring the freedom of consent obtained from members of a group with a hierarchical structure such as medical, pharmacy and nursing students, hospital and laboratory personnel, employees of the pharmaceutical industry, and members of the armed forces. In such cases the willingness to volunteer may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation or of a retaliatory response from senior members of the hierarchy in case of refusal to participate. Other vulnerable groups whose consent also needs special consideration include patients with incurable diseases, people in nursing homes, prisoners or detainees, the unemployed or people on a very low income, patients in emergency departments, some ethnic and racial minority groups, the homeless, nomads and refugees. If such categories are part of the population to be enrolled in a clinical trial, the ethics committee should consider carefully the appropriateness of the informed consent process. In a non therapeutic study, i.e. when there is no direct clinical benefit to the participant, consent must always be given by the participant and documented by his or her signature. Reference: The principles of informed consent in the current revisions of the Declaration of Helsinki and the International Ethical Guidelines for Biomedical Research Involving Human Subjects as noted in the WHO Guidelines for GCP for trials on pharmaceutical products (http://apps.who.int/medicinedocs/pdf/whozip13e/whozip13e.pdf) 21 7

8 Informed Consent Process Assent Informed consent is valid only with adults age 18 Assent is obtained from children and adults who are unable to make their own decisions regarding research participation when possible. Legal permission must be provided for the participant to enroll. The participant must verbally / in writing assent to their participation. Failure of the participant to object should not be construed as assent. Assent is the affirmative agreement to participate in research. The participant should be competent and have capacity to assent. Consent can be provided by: Surrogate One appointed to act in place of another Legally Authorized Representative (LAR) Guardian (court appointed) Durable Power of Attorney (DPA) For children who assented, they will need to be consented when they become 18 years of age 22 Informed Consent Process Assent Some states have legislation that addresses the issue of a minor's consent to medical treatment. According to the Minors (Property and Contracts) Act 1970 (NSW), a child aged 14 years or over may consent to his or her medical or dental treatment, and the consent of the minor will be effective in terms of defending an action for assault or battery relating to the treatment. The NSW Act also allows parents of children under the age of 16 to validly consent to their child's medical or dental treatment. The Consent to Medical Treatment and Palliative Care Act 1995 (SA) prescribes that an individual of 16 years of age or over can consent to medical and dental treatment 'as validly and effectively as an adult'. Provided that a medical practitioner, supported by another medical practitioner, believes that certain treatment is in the best interests of the child and the child is 'capable of understanding the nature, consequences and risks' involved, that child can validly consent to their own treatment. The SA legislation also provides that medical treatment can be administered to a child if the child's parent or guardian consents to it. The common law applies in those Australian jurisdictions that have not specifically legislated in relation to the issue of minors' consent to medical treatment. The common law position relating to a minor's competency to consent to treatment was established by the English House of Lords decision in Gillick v West Norfolk and Wisbech Area Health Authority [1986] AC 112, which was approved by the High Court of Australia in Secretary, Department of Health and Community Services v JWB and SMB (Marion's case) (1992) 175 CLR 218. In Gillick, it was held that the authority of a parent decreases as their child becomes increasingly competent. Gillick prescribes that the parental right to determine their child's treatment terminates once a child under the age of 16 is capable of fully understanding the medical treatment proposed. of consent to medical treatment.aspx 23 Informed Consent Process Non english speaking participants The investigator must prepare: A participant information sheet and consent form translated to a language understandable to the participant. Translation should be done by a certified translator and back translated into English. When using an interpreter, a written summary of the consent conversation is required. This summary may be written in English. The HREC must approve both the participant information sheet / consent form and the summary. In the case of where disability prevents participants from being able to physically sign his/her name, or in the case of illiterate participant, a person who speaks and understands English, but does not read and write, can be enrolled in a study by "making their mark" on the informed consent document. The HREC will consider these persons are likely to be vulnerable to coercion and undue influence and should determine that appropriate additional safeguards are in place when enrollment of such persons is anticipated. A person who can understand and comprehend spoken English, but is physically unable to talk or write, can be enrolled in a study using an informed consent document. The medical record document should include the method used for communication with the participant and the specific means by which the participant communicated agreement to participate in the study. An impartial witness must be present for the entire consent process and should sign and date the consent document. 24 8

9 Informed Consent Process Other participants For deaf subjects who are fluent in American Sign Language (ASL), the HREC may approve a consent process using ASL and the HREC approved written consent form. When this process is approved, the individual authorized to consent prospective participants must use an interpreter fluent in ASL to conduct the consent process and the documentation of the consent process must conform to the requirements set by the HREC. For blind subjects who read Braille, the HREC may approve a consent document prepared in Braille. In order to assure itself that a Braille consent document is accurate, the HREC may require a transcription into print text. If possible, the subject will sign the Braille consent; otherwise verbal consent will be obtained, witnessed and documented If there is any concern about an individual s cognitive ability to provide informed consent or assent, an appropriate assessment should be performed by a qualified individual. Additional approval will be required by the Guardianship Tribunal for persons 16years of age or older who are unable to provide informed consent to treatment. 25 Informed Consent Process Withdrawal The ethical principals guiding research with participants require that that no person participates in research unless their individual participation is voluntary, based upon a full disclosure of the procedures, and their continued right to withdraw at any time. An important caveat to the right to withdraw however is that data collected from a participant up to the point of withdrawal remains part of the study database. A consent document cannot give a participant the option of having data removed from the study dataset. FDA law and regulations require the collection and maintenance of complete clinical study data. This includes information on participants who withdraw from a clinical investigation, whether the participant decides to discontinue participation in the clinical trial (21 CFR 50.25(a)(8)) or is discontinued by the investigator because the participant no longer qualifies for the research. According to the ICH Good Clinical Practice guideline (E6 6.53), study protocols should include the following information: Participant withdrawal criteria (i.e., terminating investigational product treatment/trial treatment) and procedures specifying: a. When and how to withdraw participants from the trial/investigational product treatment b. The type and timing of the data to be collected for withdrawn participants c. Whether and how participants are to be replaced d. The follow up for participants withdrawn from investigational product treatment/trial treatment Protocols should also describe any special requirements related to participant withdrawal, e.g., post study safety monitoring. Unless it is important for the participant s health, do not require the participant to submit to any testing or data collection as a condition of withdrawal. Under some circumstances, e.g., pregnancy, a participant might stop receiving the study drug but stay in the study for follow up visits for safety monitoring and data collection purposes. Local regulations and ICH guidelines require consent forms to include a statement about the participant s right to withdraw from a clinical trial. References: 45 CFR (5) (8), 21 CFR 50.25(c), Withdrawal of Subjects from Research: Data Retention and Other Related Issues: OHRP Guidance (2010), Guidance for Sponsors, Clinical Investigators, and IRBs, Data Retention When Subjects Withdraw from FDA Regulated Clinical Trials (2008). 26 Informed Consent Process Termination The participant s participation in a clinical trial may be terminated without his or her consent in cases like the following: Continued participation in the clinical trial could be harmful to the participant s health, e.g., because of a side effect from the clinical trial medication. The participant becomes pregnant or becomes ill with a condition that prohibits participation. After enrollment, it is discovered that the participant does not meet the eligibility criteria, e.g., based on false information provided by the participant. The participant needs a medicine or other medical treatment that is not allowed in the clinical trial. The participant does not take, or is unable to take, the clinical trial medication as instructed, does not keep appointments, or otherwise does not adhere to protocol requirements. The participant was enrolled by error, e.g., due to misinterpretation of the eligibility criteria or during a poorly managed competitive enrollment period. The clinical trial is terminated prematurely by the investigator, research institution, sponsor, HREC, or TGA Before terminating a participant s participation, make every reasonable attempt to address the issue(s), which might or might not be under his or her control. Some flexibility might be required to retain the participant. For example, the participant s work schedule might have changed, necessitating visits at odd hours. Once a termination decision is made, first attempt to inform the participant in person or by telephone and then by that his or her participation in the study is being concluded, and explain the reason. If necessary, conduct a final visit like that for voluntary withdrawals. If a participant dies, where required, obtain a death certificate, coroner s report, or other documentation of the death. 27 9

10 Informed Consent Process Questions The following represents a sample list of questions that the participant could ask during the informed consent process: About the clinical trial What is the main purpose of the study? Why is this study important to me? What are the chances that this drug /device / health intervention will work? What kinds of risks are involved? What are the possible benefits? How much of my time will this take? How will the trial affect my daily life? Does the study involve a placebo or a treatment already on the market? What are my chances of getting the experimental product / drug / device / health intervention? Will results of the study be provided to me? About my care What kinds of tests will be done? Will they hurt? If so, for how long? How will the tests in the study compare to tests I would have outside the trial? Will I be able to continue to see my own doctor during the study? Will I be able to continue to take my regular medications during the trial? If I have side effects, can they be treated during the trial? About personal matters Who will review information collected about me during the trial? What happens if I decide to quit / withdraw from the study? Can the investigator take me out of the study even if I want to continue? About compensation and costs Do I have to pay for any part of the study? If so, will insurance cover these costs? How will I be protected? What are my options if I am injured during the study? Will transportation be provided if I need it? 28 Informed Consent Audit Findings Common audit findings: Title of the protocol not consistent Participant information sheet / consent form (PISCF) does not match the protocol (procedures listed in incorrect order) Incorrect version signed of PISCF at study visit PISCF not updated with modifications to protocol Participants not re consented with the correct version / date Poor version and date control with PISCF Missing signature / date of relevant people (PI) Incomplete PISCF. Not all essential elements included: Financial disclosure, sample size, tissue / genetic banking, secondary use of data, telephone / photo / video images not referenced, no record of verbal consent being taken 29 Informed Consent Tips Informed consent should be given at a comfortable pace, with time allowed for the participant to think it over and ask questions. The PI should make every effort to be sure that the participant understands the information they have provided. The PI can do this by having the participant fill out a questionnaire, asking the participant questions, or having the participant tell the PI about the clinical trial in their own words. Some clinical trials offer a video, audio recording, or an interactive computer module to help the participant better understand the information in the consent form. If the protocol specific testing is done the same day as informed consent documents are signed, the chronological order must be clearly documented in the medical record. ICH GCP Impartial witness a person who is independent of the trial, who cannot be unfairly influenced by people involved in the trial, who attends the informed consent process

11 Summary Defined Good Clinical Practice (GCP) Outlined the goals of GCP What is Informed Consent? Process of undertaking Informed Consent in Clinical Trials Common audit findings Tips 31 Links FURTHER INFORMATION: Jacqueline Everett Clinical Trial Governance Manager Phone: FDA TGA https://www.tga.gov.au/ ICH GCP ISO National Statement https://www.nhmrc.gov.au/guidelines publications/e72 USYD CTG University of Sydney 32 University of Sydney 33 11

GOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE

GOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE ICH E6 GCP: Consolidated Guideline: Investigator 1/7 Institutional Review Board Services ICH HARMONIZED TRIPARTITE GUIDELINE E6: GOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE 4. INVESTIGATOR 4.1 Investigator's

More information

Good Clinical Practice 101: An Introduction

Good Clinical Practice 101: An Introduction Good Clinical Practice 101: An Introduction Presented by: Lester Jao Lacorte, MD Medical Officer Commissioner s Fellow Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological

More information

Institutional Review Board

Institutional Review Board Institutional Review Board Ethical Principles of Informed Consent Informed Consent Guidelines The principle of respect for persons requires that people be given the opportunity to choose what will or will

More information

12.0 Investigator Responsibilities

12.0 Investigator Responsibilities v. 5.13.13 12.0 Investigator Responsibilities 12.1 Policy Investigators are ultimately responsible for the conduct of research. Research must be conducted according to the signed Investigator statement,

More information

University of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol

University of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol University of Hawai i Human Studies Program Guidelines for Developing a Clinical Research Protocol Following are guidelines for writing a clinical research protocol for submission to the University of

More information

CNE Disclosures. To change this title, go to Notes Master

CNE Disclosures. To change this title, go to Notes Master CNE Disclosures Successful Completion: Participants must complete an evaluation form to receive a certificate of completion Contact Hours: 1 contact hour is available to those who meet the successful completion

More information

Tip Sheet 11: Following the Guideline of the International Conference on Harmonization Good Clinical Practice (E6)

Tip Sheet 11: Following the Guideline of the International Conference on Harmonization Good Clinical Practice (E6) Tip Sheet 11: Following the Guideline of the International Conference on Harmonization Good Clinical Practice (E6) Related Accreditation Elements: I.1.D., I.1.F., I-2, I.7.B., II.2.E., II.2.F., II.4.A.,

More information

Catherine Jahrsdorfer, RN, BSN Director of Clinical Services USF Health Office of Clinical Research

Catherine Jahrsdorfer, RN, BSN Director of Clinical Services USF Health Office of Clinical Research A Practical Guide on Applying USF HRPP P&Ps in the Clinical Setting Catherine Jahrsdorfer, RN, BSN Director of Clinical Services USF Health Office of Clinical Research Learning Objectives Recognize the

More information

Miami University: Human Subjects Research General Research Application Guidance

Miami University: Human Subjects Research General Research Application Guidance Miami University: Human Subjects Research General Research Application Guidance Use the accompanying Word template for completing the research description. You must provide sufficient information regarding

More information

Human Research Protection Program Good Clinical Practice Guidance for Investigators Investigator & Research Staff Responsibilities

Human Research Protection Program Good Clinical Practice Guidance for Investigators Investigator & Research Staff Responsibilities This Guidance Document is to ensure that investigators and research personnel recognize their responsibilities associated with the conduct of human subject research by outlining their responsibilities,

More information

Application Guide to assist completion of the ACC Research Ethics Committee Application Template

Application Guide to assist completion of the ACC Research Ethics Committee Application Template Application Guide to assist completion of the ACC Research Ethics Committee Application Template A number of guiding principles govern the review of research proposals. The following provide guidance but

More information

Nova Southeastern University IRB - Consent Form Checklist Version Date: 02/17/2010

Nova Southeastern University IRB - Consent Form Checklist Version Date: 02/17/2010 Nova Southeastern University IRB - Consent Form Checklist Version Date: 02/17/2010 This form is intended to assist researchers in creating consent and assent forms. Informed consent is one of the primary

More information

Principal Investigator and Sub Investigator Responsibilities

Principal Investigator and Sub Investigator Responsibilities Principal Investigator and Sub Investigator Responsibilities I. Purpose To define the roles and responsibilities of Principal Investigators conducting research at GRU. II. Definition The term Principal

More information

RECOMMENDATION ON THE CONTENT OF THE TRIAL MASTER FILE AND ARCHIVING

RECOMMENDATION ON THE CONTENT OF THE TRIAL MASTER FILE AND ARCHIVING RECOMMENDATION ON THE CONTENT OF THE TRIAL MASTER FILE AND ARCHIVING July 2006 TABLE OF CONTENTS Page 1. Introduction 2 2. Scope 2 3. Documents to be archived 2 4. Quality of essential documents 10 5.

More information

DRAFT GUIDELINES ON AUDIO-VISUAL RECORDING OF INFORMED CONSENT PROCESS IN CLINICAL TRIAL

DRAFT GUIDELINES ON AUDIO-VISUAL RECORDING OF INFORMED CONSENT PROCESS IN CLINICAL TRIAL DRAFT GUIDELINES ON AUDIO-VISUAL RECORDING OF INFORMED CONSENT PROCESS IN CLINICAL TRIAL GUIDANCE DOCUMENT Comments/suggestions, if any, may please be submitted to the office of Drugs Controller General

More information

UNIVERSITY OF CALIFORNIA, SAN DIEGO HUMAN RESEARCH PROTECTIONS PROGRAM. DoD/DON-funded Research

UNIVERSITY OF CALIFORNIA, SAN DIEGO HUMAN RESEARCH PROTECTIONS PROGRAM. DoD/DON-funded Research UNIVERSITY OF CALIFORNIA, SAN DIEGO HUMAN RESEARCH PROTECTIONS PROGRAM DoD/DON-funded Research Policy In 2006, the Department of the Navy (DON) enhanced its human subject protection requirements, including

More information

A Principal Investigator s Guide to Responsibilities, Qualifications, Records and Documentation of Human Research University of Kentucky

A Principal Investigator s Guide to Responsibilities, Qualifications, Records and Documentation of Human Research University of Kentucky A Principal Investigator s Guide to Responsibilities, Qualifications, Records and Documentation of Human Research University of Kentucky I. Compliance with IRB and Applicable Federal Requirements A. Investigators

More information

The Study Site Master File and Essential Documents

The Study Site Master File and Essential Documents The Study Site Master File and Essential Documents Standard Operating Procedure Office of Health and Medical Research Queensland Health SOP reference: 002 Version number: 1 Effective date: 01 June 2010

More information

Research Institute Administration

Research Institute Administration PROTOCOL DEVIATIONS 229 1 of 7 PURPOSE The purpose of this policy is to define protocol deviations and the subsequent actions required by the Principal Investigator (PI) once a protocol deviation occurs

More information

WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Medical Research Involving Human Subjects

WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Medical Research Involving Human Subjects WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Medical Research Involving Human Subjects Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by

More information

Considerations for Waivers of Informed Consent and Authorization

Considerations for Waivers of Informed Consent and Authorization Considerations for Waivers of Informed Consent and Authorization Contents: Waiver of Informed Consent... 1 Office for Human Research Protections (OHRP) regulations... 1 Government projects... 1 All other

More information

EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE

EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE Purpose 1. The Clinical Trials Directive 2001/20/EC heralds certain additional responsibilities for the Medicines and Healthcare

More information

Investigator responsibilities for research conducted under the authority of the UTHSCSA Institutional Review Board (IRB)

Investigator responsibilities for research conducted under the authority of the UTHSCSA Institutional Review Board (IRB) March 1, 2006 M E M O R A N D U M F O R R E C O R D TO: FROM: SUBJECT: Deans Department Chairs Principal Investigators Brian Herman, Ph.D. Vice President for Research Investigator responsibilities for

More information

MEREDITH COLLEGE INSTITUTIONAL REVIEW BOARD GUIDELINES FOR THE PROTECTION OF HUMAN PARTICIPANTS IN RESEARCH

MEREDITH COLLEGE INSTITUTIONAL REVIEW BOARD GUIDELINES FOR THE PROTECTION OF HUMAN PARTICIPANTS IN RESEARCH MEREDITH COLLEGE INSTITUTIONAL REVIEW BOARD GUIDELINES FOR THE PROTECTION OF HUMAN PARTICIPANTS IN RESEARCH I. Introduction Recognizing its responsibility to provide measures to reasonably protect individuals

More information

RESEARCH STUDY PROTOCOL. Study Title. Name of the Principal Investigator

RESEARCH STUDY PROTOCOL. Study Title. Name of the Principal Investigator RESEARCH STUDY PROTOCOL Study Title Name of the Principal Investigator For research involving human subjects, certain elements must be included with each new IRB submission to ensure an effective review

More information

Section 5: Recordkeeping, Reporting, Non-Compliance, Unanticipated Problems, Adverse Events, Suspension, Termination

Section 5: Recordkeeping, Reporting, Non-Compliance, Unanticipated Problems, Adverse Events, Suspension, Termination Section 5: Recordkeeping, Reporting, Non-Compliance, Unanticipated Problems, Adverse Events, Suspension, Termination 5.1. Recordkeeping Policy In accordance with federal regulations (45 CFR 46.115 and

More information

Investigator Responsibilities

Investigator Responsibilities Investigator Responsibilities Standard Operating Procedure Office of Health and Medical Research Queensland Health SOP reference: 010 Version number: 1 Effective date: 01 June 2010 Review due: May 2011

More information

Guidance on IRB Continuing Review of Research

Guidance on IRB Continuing Review of Research NOTE: THIS GUIDANCE SUPERSEDES OHRP S JANUARY 15, 2007 GUIDANCE ENTITILED GUIDANCE ON CONTINUING REVIEW. CLICK HERE FOR THE JANUARY 15, 2007 GUIDANCE. Office for Human Research Protections Department of

More information

Managing Risk in Clinical Research. Dr Martha J Wrigley R&D Manager Senior Visiting Fellow University of Surrey

Managing Risk in Clinical Research. Dr Martha J Wrigley R&D Manager Senior Visiting Fellow University of Surrey Managing Risk in Clinical Research Dr Martha J Wrigley R&D Manager Senior Visiting Fellow University of Surrey Aim of the session To explore the risks associated with clinical research and understand how

More information

Human Research Seminar Series: Informed Consent Process & HIPAA Authorization Requirements

Human Research Seminar Series: Informed Consent Process & HIPAA Authorization Requirements Institutional Review Board Human Research Seminar Series: Informed Consent Process & HIPAA Authorization Requirements Thursday, October 14, 2010 Presented by: Chester Edelmann, MD Chairman Jacqueline Rowan,

More information

OFFICE OF THE ARIZONA ATTORNEY GENERAL Mark Brnovich. STATE OF ARIZONA DURABLE HEALTH CARE POWER OF ATTORNEY Instructions and Form

OFFICE OF THE ARIZONA ATTORNEY GENERAL Mark Brnovich. STATE OF ARIZONA DURABLE HEALTH CARE POWER OF ATTORNEY Instructions and Form OFFICE OF THE ARIZONA ATTORNEY GENERAL Mark Brnovich STATE OF ARIZONA DURABLE HEALTH CARE POWER OF ATTORNEY Instructions and Form GENERAL INSTRUCTIONS: Use this Durable Health Care Power of Attorney form

More information

Clinical Trials - Insurance and Indemnity

Clinical Trials - Insurance and Indemnity Policy Directive Clinical Trials - Insurance and Indemnity Document Number PD2011_006 Publication date 25-Jan-2011 Functional Sub group Corporate Administration - Governance Clinical/ Patient Services

More information

STATE OF ARIZONA DURABLE HEALTH CARE POWER OF ATTORNEY Instructions and Form

STATE OF ARIZONA DURABLE HEALTH CARE POWER OF ATTORNEY Instructions and Form STATE OF ARIZONA DURABLE HEALTH CARE POWER OF ATTORNEY Instructions and Form GENERAL INSTRUCTIONS: Use this Durable Health Care Power of Attorney form if you want to select a person to make future health

More information

Human Subjects Research (HSR) Series

Human Subjects Research (HSR) Series Human Subjects Research (HSR) Series CITI Program s HSR series consists of modules from two basic tracks, Biomedical (Biomed) and Social- Behavioral- Educational (SBE), and a set of Additional Modules

More information

Roles & Responsibilities of the Research Team

Roles & Responsibilities of the Research Team Roles & Responsibilities of the Research Team Developed by Center for Cancer Research, National Cancer Institute, NIH Endorsed by the CTN SIG Leadership Group Introduction All staff involved in clinical

More information

Ethical Principles in Clinical Research. Christine Grady Department of Bioethics NIH Clinical Center

Ethical Principles in Clinical Research. Christine Grady Department of Bioethics NIH Clinical Center Ethical Principles in Clinical Research Christine Grady Department of Bioethics NIH Clinical Center 1 Ethical principles Are these studies ethical? How do we know? Ethics of clinical research The goal

More information

CLINICAL RESEARCH PROTOCOL CHECKLIST

CLINICAL RESEARCH PROTOCOL CHECKLIST CLINICAL RESEARCH PROTOCOL CHECKLIST [taken from ICH GCP : Guidance for Industry, Good Clinical Practice: Consolidated Guidance, Revision 1 (R1) June 1996] ICH GCP, Section 6. CLINICAL TRIAL PROTOCOL AND

More information

Documentation of the Informed Consent Process. USC Office for the Protection of Research Subjects (OPRS)

Documentation of the Informed Consent Process. USC Office for the Protection of Research Subjects (OPRS) Documentation of the Informed Consent Process USC Office for the Protection of Research Subjects (OPRS) Session Overview Highlights: Purpose of Informed Consent (IC) IC Process and Documentation Witness

More information

STATE OF ARIZONA DURABLE HEALTH CARE POWER OF ATTORNEY Instructions and Form

STATE OF ARIZONA DURABLE HEALTH CARE POWER OF ATTORNEY Instructions and Form STATE OF ARIZONA DURABLE HEALTH CARE POWER OF ATTORNEY Instructions and Form GENERAL INSTRUCTIONS: Use this Durable Health Care Power of Attorney form if you want to select a person to make future health

More information

State University of New York at Canton Institutional Review Board. Sample Informed Consent Document

State University of New York at Canton Institutional Review Board. Sample Informed Consent Document State University of New York at Canton Institutional Review Board Sample Informed Consent Document The following sample informed consent document includes instructions to the person writing the document,

More information

UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER INSTITUTIONAL REVIEW BOARD EMERGENCY MEDICINE RESEARCH EXEMPTION FROM INFORMED CONSENT REQUIREMENTS

UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER INSTITUTIONAL REVIEW BOARD EMERGENCY MEDICINE RESEARCH EXEMPTION FROM INFORMED CONSENT REQUIREMENTS UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER INSTITUTIONAL REVIEW BOARD EMERGENCY MEDICINE RESEARCH EXEMPTION FROM INFORMED CONSENT REQUIREMENTS I. PURPOSE This document outlines the procedures for University

More information

DECLARATION FOR MEDICAL CARE. be a patient, and any person who may be responsible for my health, welfare, or care. When I am

DECLARATION FOR MEDICAL CARE. be a patient, and any person who may be responsible for my health, welfare, or care. When I am DECLARATION FOR MEDICAL CARE To my family, clergyman, physician, attorney, any medical facility where I may be a patient, and any person who may be responsible for my health, welfare, or care. When I am

More information

Pl"OtocolDirector: Iris Schrijver _ IRB Approval Date: _June 20 2006 IRE Expiration Date: June 19, 2007 _ STANFORD SAMPLE CONSENT FORM

PlOtocolDirector: Iris Schrijver _ IRB Approval Date: _June 20 2006 IRE Expiration Date: June 19, 2007 _ STANFORD SAMPLE CONSENT FORM Protocol Title: Molecular genetic basis of sensorineural hearing Pl"OtocolDirector: Iris Schrijver IRB Approval Date: June 20 2006 IRE Expiration Date: June 19, 2007 STANFORD SAMPLE CONSENT FORM Please

More information

Public Policy Statement: Clinical Trial Ethics

Public Policy Statement: Clinical Trial Ethics Public Policy Statement: Clinical Trial Ethics Purpose As a global healthcare company, Merck's role is first and foremost to discover, develop and provide innovative products and services that save and

More information

To IRB, or Not to IRB? That Is the Question!

To IRB, or Not to IRB? That Is the Question! To IRB, or Not to IRB? That Is the Question! A presentation by Mary Sapp, Ph.D. Assistant Vice President, Planning & Institutional Research University of Miami and Thomas K. Martin, Ph.D. Associate Vice

More information

WMA Declaration of Helsinki - Ethical

WMA Declaration of Helsinki - Ethical WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended by the: 29th WMA General

More information

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure 703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a

More information

STANDARDS OF PRACTICE (2013)

STANDARDS OF PRACTICE (2013) STANDARDS OF PRACTICE (2013) COLLEGE OF ALBERTA PSYCHOLOGISTS STANDARDS OF PRACTICE (2013) 1. INTRODUCTION The Health Professions Act (HPA) authorizes and requires the College of Alberta Psychologists

More information

Advancing research: a physician s guide to clinical trials

Advancing research: a physician s guide to clinical trials Advancing research: a physician s guide to clinical trials Recruiting and retaining trial participants is one of the greatest obstacles to developing the next generation of Alzheimer s treatments Alzheimer

More information

Technical Assistance Document 5

Technical Assistance Document 5 Technical Assistance Document 5 Information Sharing with Family Members of Adult Behavioral Health Recipients Developed by the Arizona Department of Health Services Division of Behavioral Health Services

More information

Background Definition Why do we need it? The process of obtaining informed consent A brief overview of special situations Conclusion

Background Definition Why do we need it? The process of obtaining informed consent A brief overview of special situations Conclusion Joanna Forbes Senior Clinical Research Nurse Ethical and legal considerations Background Definition Why do we need it? The process of obtaining informed consent A brief overview of special situations Conclusion

More information

Document Template #1 Adult/General Informed Consent (Rev. 9/20/2011)

Document Template #1 Adult/General Informed Consent (Rev. 9/20/2011) Document Template #1 Adult/General Informed Consent (Rev. 9/20/2011) Consent Form for Participation in the Research Study Entitled XYZ (or can be written in the XYZ study ) Funding Source: List complete

More information

ASSESSMENT OF DECISION MAKING CAPACITY IN ADULTS PARTICIPATING IN A RESEARCH STUDY 3/3/2016

ASSESSMENT OF DECISION MAKING CAPACITY IN ADULTS PARTICIPATING IN A RESEARCH STUDY 3/3/2016 DUKE UNIVERSITY HEALTH SYSTEM Human Research Protection Program ASSESSMENT OF DECISION MAKING CAPACITY IN ADULTS PARTICIPATING IN A RESEARCH STUDY 3/3/2016 Based on the ethical principle of respect for

More information

Reliance Agreement for Institutions Utilizing Stony Brook University s Institutional Review Board(s)

Reliance Agreement for Institutions Utilizing Stony Brook University s Institutional Review Board(s) Name of Organization Providing IRB Review: Stony Brook University ( SBU IRB ) Name of Institution Relying on the SBU IRB ( Institution ): Latest AAHRPP Accreditation Date (if applicable) OHRP Federal Wide

More information

WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI

WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Medical Research Involving Human Subjects Adopted by the 18 th WMA General Assembly Helsinki, Finland, June 1964 and amended by

More information

Guidance on Withdrawal of Subjects from Research: Data Retention and Other Related Issues

Guidance on Withdrawal of Subjects from Research: Data Retention and Other Related Issues Office for Human Research Protections (OHRP) Department of Health and Human Services (HHS) Guidance on Withdrawal of Subjects from Research: Data Retention and Other Related Issues This guidance represents

More information

CORD BLOOD TRANSPLANTATION STUDY EXPANDED ACCESS PROTOCOL APPENDIX A SAMPLE CONSENT FORM

CORD BLOOD TRANSPLANTATION STUDY EXPANDED ACCESS PROTOCOL APPENDIX A SAMPLE CONSENT FORM APPENDIX A SAMPLE CONSENT FORM CORD BLOOD TRANSPLANTATION (COBLT) STUDY SAMPLE CONSENT FORM FOR THE EXPANDED ACCESS PROTOCOL You (your child) are being asked to take part in a clinical research study.

More information

Clinical Trial Oversight: Ensuring GCP Compliance, Patient Safety and Data Integrity

Clinical Trial Oversight: Ensuring GCP Compliance, Patient Safety and Data Integrity Clinical Trial Oversight: Ensuring GCP Compliance, Patient Safety and Data Integrity Michelle Quaye Regulatory Manager, Advanced Therapy Trials University College London Overview The Principles of Good

More information

WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Medical Research Involving Human Subjects

WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Medical Research Involving Human Subjects Policy WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Medical Research Involving Human Subjects Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended

More information

Consent Form: Example 2 (DNA Sequencing)

Consent Form: Example 2 (DNA Sequencing) Consent Form: Example 2 (DNA Sequencing) Important note: This model language was developed for the NHGRI Medical Sequencing Project (MSP). It is included here only as an example of how to describe a sequencing

More information

Guidelines approved under Section 95A of the Privacy Act 1988. December 2001

Guidelines approved under Section 95A of the Privacy Act 1988. December 2001 Guidelines approved under Section 95A of the Privacy Act 1988 December 2001 i Commonwealth of Australia 2001 ISBN Print: 1864961074 Online: 1864961139 This work is copyright. Apart from any use as permitted

More information

Principal Investigator Responsibilities for Education and Social/Behavioral Researchers

Principal Investigator Responsibilities for Education and Social/Behavioral Researchers Principal Investigator Responsibilities for Education and Social/Behavioral Researchers Introduction The purpose of this module is to provide a basic understanding of the responsibilities of the principal

More information

1. Study title Is the title self explanatory to a layperson? If not, a simplified title should be included.

1. Study title Is the title self explanatory to a layperson? If not, a simplified title should be included. These guidelines apply to all research projects where human subjects are involved in the study GUIDELINES FOR RESEARCHERS PATIENT INFORMATION SHEET & CONSENT FORM The guidance, which follows, applies primarily

More information

If you are signing for a minor child, you refers to your child throughout the consent document.

If you are signing for a minor child, you refers to your child throughout the consent document. CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY Adult Patient or Parent, for Minor Patient INSTITUTE: National Cancer Institute PRINCIPAL INVESTIGATOR: Raffit Hassan, M.D. STUDY TITLE: Tissue Procurement

More information

Health Canada s GCP Compliance Program. GCP Information Sessions November 2010

Health Canada s GCP Compliance Program. GCP Information Sessions November 2010 Your Health and Safety... Our priority Votre santé et votre Securité notre priorité Health Canada s GCP Compliance Program GCP Information Sessions November 2010 Objective To describe the role that Health

More information

Code of Professional Conduct and Ethical Practice

Code of Professional Conduct and Ethical Practice Code of Professional Conduct and Ethical Practice Version 2 For implementation 1 January 2014 Exercise & Sports Science Australia Ltd (ESSA) ACN 053 849 460 ABN 14 053 849 460 Locked Bag 102 Albion Queensland

More information

WHAT ARE THE SPECIFIC DIFFERENCES BETWEEN VERSION 5.5 AND VERSION 5.6 OF THE RESEARCH ETHICS COMMITTEE STANDARD APPLICATION FORM?

WHAT ARE THE SPECIFIC DIFFERENCES BETWEEN VERSION 5.5 AND VERSION 5.6 OF THE RESEARCH ETHICS COMMITTEE STANDARD APPLICATION FORM? Application Form Cover Sheet - Addition of Application Version No. in Version 5.6 - Addition of Application Date in Version 5.6 - Remove Principal Investigator (deletion) - Remove Applicant s Signature

More information

[Informed Consent Form for ] Name the group of individuals for whom this consent is written. Explanation Example

[Informed Consent Form for ] Name the group of individuals for whom this consent is written. Explanation Example [YOUR INSTITUTIONAL LETTERHEAD] Please do not submit consent forms on the WHO letter head [Name of Principle Investigator] [Informed Consent Form for ] Name the group of individuals for whom this consent

More information

Conduct of clinical Trials Communication of

Conduct of clinical Trials Communication of PrinciPles on Conduct of clinical Trials Communication of clinical Trial results Table of Contents Preamble...1 Commitment to Protecting Research Participants...5 Conduct of Clinical Trials...7 Ensuring

More information

IF YOU HAVE ANY QUESTIONS ABOUT THIS NOTICE OR IF YOU NEED MORE INFORMATION, PLEASE CONTACT OUR PRIVACY OFFICER:

IF YOU HAVE ANY QUESTIONS ABOUT THIS NOTICE OR IF YOU NEED MORE INFORMATION, PLEASE CONTACT OUR PRIVACY OFFICER: NOTICE OF PRIVACY PRACTICES COMPLETE EYE CARE THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED OR DISCLOSED AND HOW YOU CAN GET ACCESS TO THIS INFORMATION. PLEASE REVIEW IT CAREFULLY.

More information

UC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part IV Criteria for Review. Cindy Gates IRB Administration

UC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part IV Criteria for Review. Cindy Gates IRB Administration UC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part IV Criteria for Review Cindy Gates IRB Administration Tips for Reviewer s Comments - Comments should be easily transferrable

More information

Instructions for Form: Application for Claim of Exemption

Instructions for Form: Application for Claim of Exemption Instructions for Form: Application for Claim of Exemption In order to decide whether your activity involves research that may be reviewed and approved at the exempt level, review the following information.

More information

Adventist HealthCare, Inc.

Adventist HealthCare, Inc. IRB POLICY ON HUMAN RESEARCH PROTECTION (HRP) AND GOOD CLINICAL PRACTICE (GCP) TRAINING Collaborative Institutional Training Initiative (CITI) Requirements at Adventist Healthcare, Inc. I. Required Human

More information

Site Initiation and Close Out (Sponsored Clinical Trials)

Site Initiation and Close Out (Sponsored Clinical Trials) Site Initiation and Close Out (Sponsored Clinical Trials) Standard Operating Procedure Office of Health and Medical Research Queensland Health SOP reference: 008 Version number: 1 Effective date: 01 June

More information

JOHNS HOPKINS NOTICE OF PRIVACY PRACTICES FOR HOPKINS ELDERPLUS/PROGRAM OF ALL-INCLUSIVE CARE FOR THE ELDERLY (PACE)

JOHNS HOPKINS NOTICE OF PRIVACY PRACTICES FOR HOPKINS ELDERPLUS/PROGRAM OF ALL-INCLUSIVE CARE FOR THE ELDERLY (PACE) JOHNS HOPKINS NOTICE OF PRIVACY PRACTICES FOR HOPKINS ELDERPLUS/PROGRAM OF ALL-INCLUSIVE CARE FOR THE ELDERLY (PACE) Effective Date: September 1, 2013 THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT

More information

Investigational Drugs: Investigational Drugs and Biologics

Investigational Drugs: Investigational Drugs and Biologics : I. PURPOSE The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics to ensure that adequate safeguards are in place

More information

ALLOW NATURAL DEATH/WITHHOLDING AND/OR WITHDRAWING L I F E - S U S T A I N I N G T R E A T M E N T / NON-BENEFICIAL CARE AND RESUSCITATION POLICY

ALLOW NATURAL DEATH/WITHHOLDING AND/OR WITHDRAWING L I F E - S U S T A I N I N G T R E A T M E N T / NON-BENEFICIAL CARE AND RESUSCITATION POLICY PURPOSE SUPPORTIVE DATA To specify the parameters within which decisions regarding the withholding and/or withdrawing of life-sustaining treatment/non beneficial care and/or no initiation of cardiopulmonary

More information

Ochsner Institutional Review Board (IRB) Written Procedures

Ochsner Institutional Review Board (IRB) Written Procedures Ochsner Institutional Review Board (IRB) Written Procedures Date of Revision: September 16, 2011 (click here for Revision History) Note: When possible, references and appendix material are hyperlinked

More information

AUSTRALIAN CLINICAL PSYCHOLOGY ASSOCIATION CODE OF PROFESSIONAL ETHICS

AUSTRALIAN CLINICAL PSYCHOLOGY ASSOCIATION CODE OF PROFESSIONAL ETHICS AUSTRALIAN CLINICAL PSYCHOLOGY ASSOCIATION CODE OF PROFESSIONAL ETHICS Purpose This Code of Professional Ethics provides principles and guidelines that should be observed by all members of the Australian

More information

UK Implementation of the EU Clinical Trial Directive 2001/20/EC:

UK Implementation of the EU Clinical Trial Directive 2001/20/EC: UK Implementation of the EU Clinical Trial Directive 2001/20/EC: GCP Aspects. Dr. Colin Wilsher, FRQA. BARQA GCP Committee Chairman; & Pfizer Worldwide Development Quality Assurance. GIQAR, Roma, October

More information

Harris County - Texas HIPAA Notice of Privacy Practices

Harris County - Texas HIPAA Notice of Privacy Practices Harris County - Texas HIPAA Notice of Privacy Practices Effective Date: September 23, 2013. THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED AND HOW YOU CAN GET ACCESS

More information

HANDBOOK FOR GOOD CLINICAL RESEARCH PRACTICE (GCP) GUIDANCE FOR IMPLEMENTATION

HANDBOOK FOR GOOD CLINICAL RESEARCH PRACTICE (GCP) GUIDANCE FOR IMPLEMENTATION HANDBOOK FOR GOOD CLINICAL RESEARCH PRACTICE (GCP) GUIDANCE FOR IMPLEMENTATION WHO Library Cataloguing-in-Publication Data Handbook for good clinical research practice (GCP): Guidance for implementation

More information

OHIO DURABLE POWER OF ATTORNEY FOR HEALTH CARE (Ohio Revised Code 1337.11 to 1337.17)

OHIO DURABLE POWER OF ATTORNEY FOR HEALTH CARE (Ohio Revised Code 1337.11 to 1337.17) OHIO DURABLE POWER OF ATTORNEY FOR HEALTH CARE (Ohio Revised Code 1337.11 to 1337.17) The following Notice to Adult Executing This Document (Durable Power of Attorney for Health Care) is required by Ohio

More information

History and Principles of Good Clinical Practice

History and Principles of Good Clinical Practice History and Principles of Good Clinical Practice Cristina E. Torres, Ph.D. Social Science Professor, UPM-NIH FERCAP Coordinator ICH: International Conference on Harmonization GCP: Good Clinical Practices

More information

The Health Insurance Portability and Accountability Act (HIPAA) Excerpted from the UTC IRB Policy

The Health Insurance Portability and Accountability Act (HIPAA) Excerpted from the UTC IRB Policy The Health Insurance Portability and Accountability Act (HIPAA) Excerpted from the UTC IRB Policy June 2008 Table of Contents PART V: The Health Insurance Portability and Accountability Act (HIPAA)...

More information

RE: Human Research Subject Protections Under Federal Wide Assurance (FWA) FWA-00000068 and Multiple Project Assurance (MPA) M-1169

RE: Human Research Subject Protections Under Federal Wide Assurance (FWA) FWA-00000068 and Multiple Project Assurance (MPA) M-1169 Office of the Secretary DEPARTMENT OF HEALTH & HUMAN SERVICES Office of Public Health and Science Office for Human Research Protections The Tower Building 1100 Wootton Parkway, Suite 200 Rockville, Maryland

More information

Taking Part in Research at University Hospitals Birmingham

Taking Part in Research at University Hospitals Birmingham University Hospitals Birmingham NHS Foundation Trust The Trust provides free monthly health talks on a variety of medical conditions and treatments. For more information visit www.uhb.nhs.uk or call 0121

More information

Guidance for Industry Investigator Responsibilities Protecting the Rights, Safety, and Welfare of Study Subjects

Guidance for Industry Investigator Responsibilities Protecting the Rights, Safety, and Welfare of Study Subjects Guidance for Industry Investigator Responsibilities Protecting the Rights, Safety, and Welfare of Study Subjects U.S. Department of Health and Human Services Food and Drug Administration Center for Drug

More information

To Certify or Not to Certify

To Certify or Not to Certify To Certify or Not to Certify Sandra Halvorson, BA, CCRP Clinical Research Coordinator II CIBMTR Minneapolis Campus Sue Logan, BS, CCRP Clinical Research Coordinator II CIBMTR Minneapolis Campus November

More information

GOOD CLINICAL PRACTICE*)

GOOD CLINICAL PRACTICE*) GOOD CLINICAL PRACTICE*) Guideline Title Good Clinical Practice*) Legislative basis Directive 75/318/EEC as amended Date of first adoption July 1990 This version July 1996 Date of entry into January 1997

More information

DURABLE POWER OF ATTORNEY FOR HEALTH CARE

DURABLE POWER OF ATTORNEY FOR HEALTH CARE ELDER LAW & DISABILITY RIGHTS SECTION DURABLE POWER OF ATTORNEY FOR HEALTH CARE I,, am of sound mind, and I (Print or type your full name) voluntarily make this designation. APPOINTMENT OF PATIENT ADVOCATE

More information

To Certify or Not to Certify Sandra Halvorson, BA, CCRP

To Certify or Not to Certify Sandra Halvorson, BA, CCRP To Certify or Not to Certify Sandra Halvorson, BA, CCRP Clinical Research Coordinator II CIBMTR Minneapolis Campus Sue Logan, BS, CCRP Clinical Research Coordinator II We have no financial relationships

More information

SUGGESTIONS & REQUIREMENTS For Medical Power of Attorney & Completing the Texas Will to Live Form

SUGGESTIONS & REQUIREMENTS For Medical Power of Attorney & Completing the Texas Will to Live Form SUGGESTIONS & REQUIREMENTS For Medical Power of Attorney & Completing the Texas Will to Live Form 1. This Medical Power of Attorney (also known as the Health Care Agent Designation Form) allows you to

More information

Claim of Exemption Form Page 1 of 6

Claim of Exemption Form Page 1 of 6 Claim of Exemption Form Page 1 of 6 Principal Investigator: Phone: Project or Protocol Title: Contact Person: Address: Phone: Fax: E-mail: Copy of Principal Investigator s CV attached SPONSOR / FUNDING

More information

LIVING WILL AND DURABLE POWER OF ATTORNEY FOR HEALTH CARE

LIVING WILL AND DURABLE POWER OF ATTORNEY FOR HEALTH CARE LIVING WILL AND DURABLE POWER OF ATTNEY F HEALTH CARE Date of Directive: Name of person executing Directive: Address of person executing Directive: A Living Will A Directive to Withhold or to Provide Treatment

More information

RESEARCH INVOLVING HUMAN SUBJECTS

RESEARCH INVOLVING HUMAN SUBJECTS RESEARCH INVOLVING HUMAN SUBJECTS GUIDELINES FOR IRBS EXECUTIVE SUMMARY Principle 1. There is general agreement internationally that human biomedical research involving risk of harm to human subjects should

More information

FDA Audit Guidelines. University of Miami. Office of the Vice Provost for Research

FDA Audit Guidelines. University of Miami. Office of the Vice Provost for Research FDA Audit Guidelines University of Miami Office of the Vice Provost for Research FDA Audit Guidelines Contents INTRODUCTION 3 VICE PROVOST FOR RESEARCH ROLE IN FDA AUDITS 3 PRE-AUDIT REVIEW 3 INSPECTION

More information

Northwest Cardiology Associates 400 W. Northwest Hwy Barrington, IL 60010 847.382.4600 Fax 847.382.1771. HIPAA Notice of Privacy Practices ( Notice )

Northwest Cardiology Associates 400 W. Northwest Hwy Barrington, IL 60010 847.382.4600 Fax 847.382.1771. HIPAA Notice of Privacy Practices ( Notice ) Northwest Cardiology Associates 400 W. Northwest Hwy Barrington, IL 60010 847.382.4600 Fax 847.382.1771 HIPAA Notice of Privacy Practices ( Notice ) THIS NOTICE DESCRIBES HOW INFORMATION ABOUT YOU MAY

More information

Eye Clinic of Bellevue, LTD. P.S. Privacy Policy EYE CLINIC OF BELLEVUE LTD PS NOTICE OF INFORMATION PRACTICES

Eye Clinic of Bellevue, LTD. P.S. Privacy Policy EYE CLINIC OF BELLEVUE LTD PS NOTICE OF INFORMATION PRACTICES Eye Clinic of Bellevue, LTD. P.S. Privacy Policy EYE CLINIC OF BELLEVUE LTD PS NOTICE OF INFORMATION PRACTICES Date of Last Revision: 4/8/03 Effective Date: Immediately This information is made available

More information

Guide for Research Sites Seeking Accreditation

Guide for Research Sites Seeking Accreditation Guide for Research Sites Seeking Accreditation (For research sites that only conduct research and do not have their own IRBs) November 16, 2010 Purpose of the Guide The accreditation process for most research

More information